The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA

Phase 3

Completed

• Conditions: Unstable Intertrochanteric Fracture; Pertrochanteric Fracture of Femur, Closed
• Interventions: Drug: Teriparatide; Drug: Placebo; Dietary Supplement: Calcium supplement; Dietary Supplement: Vitamin D

• Registration Number: NCT03133195
• Lead Sponsor: King Chulalongkorn Memorial Hospital

Brief Summary

Phase III, prospective, randomized, parallel, double blind, placebo-controlled study to determine whether Teriparatide can accelerate bone healing in unstable intertrochanteric fracture patients treated with Proximal Femoral Nail Antirotation (PFNA) assessed by radiographic and clinical outcomes.

Detailed Description

Patients will undergo screening assessment to determine the eligibility for study participation and will be randomized in 1:1 ratio to receive Teriparatide 20 μg or placebo subcutaneous once daily for 12 weeks.

All patients will receive supplements of 1000 mg/day of elemental calcium and 20,000 IU/week of vitamin D2.

Patients will be scheduled to clinic visit for radiographic and clinical assessment at 2, 6,12 and 24 weeks postoperatively. Each participant will be in the study for 6 months in total.

Study Timeline

• Study First Submitted: 2017-04-21
• Study First Submitted QC: 2017-04-27
• Study First Posted: 2017-04-28
• Study Start: 2017-05-17
• Primary Completion: 2022-06-01
• Study Completion: 2023-07-01
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-13
• Last Update Posted: 2025-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Male and female patient, age ≥ 50 years at the time of screening
2. Unstable intertrochanteric fracture (AO/OTA 31-A2 and 31-A3)
3. Treated by proximal femoral nail antirotation (PFNA)

Exclusion Criteria

1. Known hypersentivity to teriparatide or any form of PTH or analogue
2. Metabolic bone disease other than primary osteoporosis (including Hyper Parathyroidism and Paget's disease of bone)
3. Increased baseline risk of osteosarcoma (Paget's disease of the bone, previous primary skeletal malignancy, or skeletal exposure to therapeutic irradiation)
4. History of malignant neoplasm in the 5 years prior to the study (with the exception of superficial basal cell carcinoma or squamous cell carcinoma) and carcinoma in situ of the uterine cervix treated less than 1 year prior to the study.
5. Pre-existing of hypercalcemia (total serum calcium >10.5 mg/dL or 2.6 mmol/L)
6. Abnormally elevated serum intact parathyroid hormone at screening (serum PTH > 70 pg/mL)
7. Severe vitamin D deficiency (25-hydroxyvitamin D < 12 ng/mL)
8. Unexplained elevations of alkaline phosphatase (ALP > 120 UL)
9. Severe renal impairment (CrCL < 30 mL/min)
10. Current treatment with digoxin and necessary to continue use during the study
11. Concurrent treatment with oral bisphosphonates, selective estrogen receptor modulator (SERMs), calcitonin, estrogen (oral, transdermal, or injection), progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and active vitamin D3 analogs. (Previous treatment is allowed but must be discontinued at screening)
12. Previous treatment with strontium ranelate for any duration, intravenous bisphophonates within 12 months prior to the screening date, and/or denosumab within 6 months prior to the screening.
13. Previous treatment with teriparatide, PTH or other PTH analogs, or prior participation in any other clinical trial studying teriparatide, PTH or other PTH analogs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Teriparatide	Teriparatide	Teriparatide 20 μg subcutaneous once daily for 12 weeks
Teriparatide	Calcium supplement	Teriparatide 20 μg subcutaneous once daily for 12 weeks
Teriparatide	Vitamin D	Teriparatide 20 μg subcutaneous once daily for 12 weeks
Placebo	Placebo	Placebo subcutaneous once daily for 12 weeks
Placebo	Calcium supplement	Placebo subcutaneous once daily for 12 weeks
Placebo	Vitamin D	Placebo subcutaneous once daily for 12 weeks

Primary Outcome Measures

Name	Time	Method
Time to healing assessed by radiographic evidence	from randomization, assessed up to 24 months	Fracture is judged to be healed radiographically if bridging callus was evident on 3 of 4 cortices as seen on two views (cortical bridging of three cortices)

Secondary Outcome Measures

Name	Time	Method
Clinical evidence of healing assessed by weight bearing ability as one of functional outcomes	from randomization, assessed up to 24 months	Weight bearing ability (Non weight bearing, Partial weight bearing, Full weight bearing)
Clinical evidence of healing assessed by Harris Hip Score as one of functional outcomes	from randomization, assessed up to 24 months	Harris Hip Score (90-100: Excellent, 80-89: Good, 70-79: Fair, \<70 poor)
Clinical evidence of healing assessed by walking ability as one of functional outcomes	from randomization, assessed up to 24 months	Walking ability (Independent walking, Assisted walking, Bedridden)

Trial Locations

Locations (1)

Faculty of Medicine Chulalongkorn University; 🇹🇭 Bangkok, Thailand